New medicine for the prevention of migraine
Monoclonal antibody Emgality recommended for marketing authorisation
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Emgality (galcanezumab), a monoclonal antibody for the prevention of migraine. Emgality belongs to a new class of medicines that work by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that is involved in migraine attacks.
It is estimated that approximately 15% of the population in the European Union suffers from migraine. Patients experience recurrent episodes of intense, throbbing headache, most often only on one side of the head. Sometimes, the pain is preceded by visual or sensory disturbances known as an ‘aura’. Many people also experience nausea, vomiting and increased sensitivity to light or sound. Migraine can substantially impair a patient’s ability to function physically, at work or school, and socially.
The exact cause of migraine is unknown, but it is believed to be a neurovascular disorder with disease mechanisms both within the brain and the blood vessels of the head. It is most frequent in women and has a strong genetic component.
Emgality will be available as a solution for injection intended only for patients who have at least 4 migraine days per month. The benefits and safety of Emgality were studied in three pivotal trials involving 1,780 patients with episodic migraine and 1,117 with chronic migraine. After six months of treatment, patients with episodic migraine showed a reduction of 1.9 monthly migraine days on average compared to placebo. For patients with chronic migraine the reduction was 2 days. The most common side effects are pain and reactions at the injection site, vertigo and constipation.
Emgality is the second monoclonal antibody therapy for the prevention of migraine to be recommended for authorisation, following the positive opinion for Aimovig (erenumab) in May 2018. There is no cure for migraine and these two medicines widen the therapeutic options for this disease. There are other available treatments to tackle the symptoms and reduce the frequency of migraine days. However, existing preventative treatments do not always work well and may have unpleasant side effects.
The opinion adopted by the CHMP is an intermediary step on Emgality’s path to patient access. The CHMP opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once a marketing authorisation has been granted, decisions about price and reimbursement will take place at the level of each Member State, taking into account the potential role/use of this medicine in the context of the national health system of that country.
- The applicant for Emgality is Eli Lilly Nederland B.V.
|New medicine for the prevention of migraine||(English only)||21/09/2018|
Latest News from
ESMA data analysis values EU derivatives market at €660 trillion with central clearing increasing significantly19/10/2018 15:10:00
The European Securities and Markets Authority (ESMA) has published its first Annual Statistical Report on the European Union’s (EU) derivatives markets.
Digital single market: a directory of European films to facilitate on-line access19/10/2018 14:10:00
Mariya Gabriel, the Commissioner for Digital Economy & Society, has presented the prototype of a directory of European films, a key action of the Digital4Culture strategy which is also part of the European Year of Cultural Heritage 2018.
Improving economic governance in the EU19/10/2018 13:10:00
At its October plenary session, the EESC adopted a package of three opinions on EU economic governance, providing European decision-makers with new input for the ongoing discussions on deepening Economic and Monetary Union (EMU) and the next European Semester exercise.
European Council meetings on 17 and 18 October 201819/10/2018 12:10:00
Remarks by President Donald Tusk after the European Council meetings
Relocation of European Medicines Agency & European Banking Authority18/10/2018 15:25:00
Today the Permanent Representatives Committee (Coreper) approved, on behalf of the Council, an agreement with the European Parliament on the text of the regulations for the relocation of the European Medicines Agency (EMA) to Amsterdam, and of the European Banking Authority (EBA) to Paris.
DiscoverEU: 12,000 additional free tickets available for 18-year-olds to discover Europe18/10/2018 13:25:00
Following the success of the first round of DiscoverEU, the European Commission will launch a second competition for free tickets on 29 November 2018.
EASO publishes a Country of Origin Information (COI) report on the security situation in Pakistan17/10/2018 14:25:00
The European Asylum Support Office has published a Country of Origin Information Report entitled ‘Pakistan security situation’. TThe report provides information relevant for the protection status determination of Pakistani asylum seekers.
Lumpy skin disease in cattle: from containment to elimination17/10/2018 12:25:00
EFSA has assessed the most effective strategies for eliminating lumpy skin disease (LSD) now that the outbreaks in south-eastern Europe have been contained.
Chemical weapons: the Council adopts a new sanctions regime17/10/2018 09:25:00
The Council adopted a new regime of restrictive measures to address the use & proliferation of chemical weapons. This decision is a direct follow-up to the conclusions of the European Council of 28 June 2018.